Response
Dr Kessler has raised an important issue to consider in formulating any strategy for targeted acute therapy as well as for primary or secondary prevention. We should first clarify that we did not intend for a Thrombolysis in Myocardial Infarction (TIMI) risk score Ն6 to be taken as a clinical threshold but rather used this score only to give the reader a sense of the distribution of mortality risk between the Ϸ10% of the population at each of the 2 extremes. 1 To the contrary, we deliberately reserved decisions regarding appropriate clinical thresholds along this spectrum for the individual clinician and institution. Furthermore, simple dichotomization of the risk score loses discriminatory information that is likely to be useful in clinical decisions.
Nevertheless, as we consider application of the TIMI risk score for ST-elevation myocardial infarction (STEMI) for specific clinical pathways (eg, development of a triage rule) Dr Kessler's comments are relevant. It is common in medical decision-making to target a high-risk population for whom a specific intervention may offer the greatest absolute benefit. This "high-risk" approach focuses resources on a small portion of the overall population at risk (the upper tail of a Gaussian distribution), often in an effort to maximize cost-efficiency or to avoid exposure to potential complications of therapy. 2 However, as Dr Kessler points out, the majority of events may occur in the middle-risk group that constitutes the greatest proportion of the population. Though the number needed to treat to avoid each event falls as patient risk increases, so too does the number of patients at risk. These important points serve as a reminder that interventions targeted at more modest reduction in absolute risk across a greater proportion of the population may achieve a greater impact on the number of lives saved. 2 The limitation of such a strategy is that lower-risk patients with little to gain may be subjected to treatments with associated discomfort and risks. For example, while the categorization suggested by Dr Kessler might capture a group with an average risk of 10.8%, there is an Ϸ8-fold gradient in mortality risk within the group.
We agree with Dr Kessler that development of an optimal strategy must take into account not only the magnitude but also the distribution of risk, as well as the benefits, costs, and hazards of therapy.
